Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as we…
At Novartis, we celebrate life and recognize moments that matter. One of the most life-changing moments our associates experience is becoming a parent and welcoming new life into their lives. In July 2019, we introduced equal paid parental leave of at …
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved DNDi wi…
Majara, a 32-year-old woman from Greenville, North Carolina, in the US, vividly remembers the times when her sickle cell pain crises gripped her body so badly she couldn’t move. “It felt like a dump truck had actually fallen on my body and was just sit…
Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as annualized relapse rate (ARR)1 Ofatumumab is a novel B-cell …
For Kassahun, a used clothing merchant in Ethiopia, managing his diabetes is something of an obstacle course. In the rural area where he lives, there are no doctors specialized in treating the disease, which if poorly managed can spark a host of other …
Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading phase1 For the more than 20 million people worldwide who…
Novartis is reimagining how it collaborates with law firms and legal services providers alike with the bold ambition to redefine shared value in its collaborations while at the same time driving more diversity and inclusion in the legal profession. “We…
FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1 Substantial unmet need exists among patients with METex14 m…
StatementFeb 05, 2020We are aware of the recent Ministry of Health (MoH) announcement, that five EU states (Belgium, the Netherlands, Luxembourg, Austria and Ireland) have issued a joint statement regarding our Global Managed Access Program (MAP). In …